Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria

Journal of Hypertension

Volumn 28, Issue 1, 2010, Pages 186-193

  Weir, Matthew R ^a   Hollenberg, Norman K ^b   Zappe, Dion H ^c   Meng, Xiangyi ^c   Parving, Hans Henrik ^d,e   Viberti, Giancarlo ^f   Remuzzi, Giuseppe ^g  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Rigshospitalet   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

African American; Albuminuria; Blood pressure; Hypertension; Valsartan

Indexed keywords

ALBUMIN; VALSARTAN;

ADULT; AFRICAN AMERICAN; AGED; ALBUMINURIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; URINARY EXCRETION;

EID: 73849143844     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328332bd61     Document Type: Article

References (16)

1. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al., African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285:2719-2728.
2. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, et al. Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003; 163:525-541.
3. Flack JM, Mensah GA, Ferrario CM. Using angiotensin converting enzyme inhibitors in African-American hypertensives: a new approach to treating hypertension and preventing target-organ damage. Curr Med Res Opin 2000; 16:66-79.
4. Weir MR, Gray JM, Paster R,Saunders E. Differing mechanisms ofaction of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension 1995; 26:124-130.
5. Weir MR. Population characteristics and the modulation of the renin-angiotensin system in the treatment of hypertension. J Hum Hypertens 1997; 11:17-21.
6. Weir MR, Chrysant SG, McCarron DA, Canossa-Terris M, Cohen JD, Gunter PA, et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension 1998; 31:1088-1096.
7. Hollenberg NK, Parving HH, Viberti G, Remuzzi G, Ritter S, Zelenkofske S, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25:1921-1926.
8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Hypertension 2003; 42:1206-1252.
9. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998; 15:539-553.
10. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1):S1-S266.
11. Weir MR. Salt intake and hypertensive renal injury in African-Americans. A therapeutic perspective. Am J Hypertens 1995; 8:635-644.
12. Aviv A, Hollenberg NK, Weder A. Urinary potassium excretion and sodium sensitivity in blacks. Hypertension 2004; 43:707-713.
13. Mokwe E, Ohmit SE, Nasser SA, Shafi T, Saunders E, Crook E, et al. Determinants of blood pressure response to quinapril in black and white hypertensive patients: the Quinapril Titration Interval Management Evaluation trial. Hypertension 2004; 43:1202-1207.
14. Chrysant SG, Weir MR, Weder AB, McCarron DA, Canossa-Terris M, Cohen JD, et al. There are no racial, age, sex, or weight differences in the effect of salt on blood pressure in salt-sensitive hypertensive patients. Arch Intern Med 1997; 157:2489-2494.
15. Price DA, Fisher ND, Lansang MC, Stevanovic R, Williams GH, Hollenberg NK. Renal perfusion in blacks: alterations caused by insuppressibility of intrarenal renin with salt. Hypertension 2002; 40:186-189.
16. Willemsen JM, Rabelink TJ, Boer P, Gaillard CA. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment. J Hum Hypertens 2004; 18:857-863.